Better together: epcoritamab boosts R2 in FL
In this issue of Blood, Falchi et al 1 reported the results of arm 2 of EPCORE NHL-2 evaluating fixed-duration epcoritamab with rituximab and lenalidomide (R2) in relapsed/refractory (R/R) follicular lymphoma (FL) in an openlabel, multicenter, phase 1b/2 study.The authors showed that the addition of epcoritamab to R2 was safe with promising signals of efficacy.
Authors
- Umberto Vitolo (ORCID: https://orcid.org/0000-0001-7772-2747)
- Francesca Bonello (ORCID: https://orcid.org/0000-0001-5758-2791)
Institutions
- Candiolo Cancer Institute (IT)
Publication Details
- Journal
- Blood
- Published
- 2025-11-27
- DOI
- https://doi.org/10.1182/blood.2025031236
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00